Valuation: ADC Therapeutics SA

Market Cap 181M 162M 151M 137M 259M 17.54B 260M 1.82B 709M 8.92B 681M 666M 28.67B P/E 2026 *
-1.87x
P/E 2027 * -2.1x
Enterprise Value 181M 162M 151M 137M 259M 17.54B 260M 1.82B 709M 8.92B 681M 666M 28.67B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.78x
Free-Float
83.9%
Yield 2026 *
-
Yield 2027 * -
1 day+11.81%
1 week+16.39%
Current month+16.39%
1 month+4.41%
3 months+5.19%
6 months-61.83%
Current year-59.77%
1 week 1.06
Extreme 1.06
1.44
1 month 1.01
Extreme 1.01
1.44
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.359908
6.04
5 years 0.36
Extreme 0.359908
32
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 2022-05-08
Director of Finance/CFO 54 2022-12-18
Chief Tech/Sci/R&D Officer 52 2024-09-30
Director TitleAgeSince
Director/Board Member 67 2019-05-31
Director/Board Member 53 2018-05-31
Chairman 59 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Chief Executive Officer

675,000 0.5307%
6/30/26 Free

Chief Financial Officer

203,700 0.1602%
6/30/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
+11.81%+16.39%-67.05%+69.05% 181M
+4.16%+4.16%+49.37%+94.17% 74.68B
-16.03%-16.35%+2.44%+50.75% 58.7B
-1.98%+0.96%+3.89%+31.93% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -0.59%-0.32%+31.67%+144.20% 38.63B
Weighted average by Cap. -2.09%-1.56%+49.10%+144.79%

Financials

2026 *2027 *
Net sales 80.65M 72.06M 67.23M 61.06M 115M 7.8B 116M 808M 316M 3.97B 303M 296M 12.75B 102M 91.11M 85M 77.21M 145M 9.86B 146M 1.02B 399M 5.02B 383M 375M 16.13B
Net income -120M -107M -99.92M -90.76M -171M -11.6B -172M -1.2B -469M -5.9B -450M -440M -18.96B -118M -105M -98.16M -89.16M -168M -11.39B -169M -1.18B -461M -5.79B -442M -433M -18.62B
Net Debt - -
Projected Income Statement - Annual - ADC Therapeutics SA
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
26-10-07 $1.420 +11.81% 1,750,770
26-10-06 $1.270 +3.25% 1,352,795
26-10-05 $1.230 +8.85% 1,752,161
26-10-02 $1.130 +4.63% 1,320,588
26-10-01 $1.080 -11.48% 862,274
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - ADC Therapeutics SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.420USD
Average target price
3.333USD
Spread / Average Target
+134.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ADC Therapeutics SA
  1. Stock Market
  2. Stocks
  3. ADCT Stock